Vinca Alkaloids for Idiopathic Thrombocytopenic Purpura
Authors: Madhavan V. Pillai, Cory D. Spencer, Takuo Sonoda
Journal: Annals of Internal Medicine (1984)

Letters and Corrections1 July 1984Vinca Alkaloids for Idiopathic Thrombocytopenic PurpuraMADHAVAN V. PILLAI, M.D., CORY D. SPENCER, M.D., TAKUO SONODA, M.D.MADHAVAN V. PILLAI, M.D.Search for more papers by this author, CORY D. SPENCER, M.D.Search for more papers by this author, TAKUO SONODA, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-1-149_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Ahn and coworkers (1) have reported interesting observations on the results of slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. However, several points crucial for an objective analysis are not clarified in their data. Although the authors define "excellent" and "good" responses, the pretreatment platelet counts are not mentioned for these patients. It is very important to specify what the precise pretreatment was. Obviously, a rise to 130 000/mm3 from 120 000/mm3 or 20 000/mm3 have different implications.Emphasis on the numerical correction of platelet counts in asymptomatic patients with chronic idiopathic thrombocytopenic...References1. AHNHARRINGTONMYLVAGANAMALLENPALL YWRLL. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med. 1984;100:192-6. LinkGoogle Scholar2. MCMILLAN R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981;19:1135-47. CrossrefGoogle Scholar3. PICOZZIROESKEGREGER VWW. Fate of therapy failures in adult idiopathic thrombocytopenic purpura. Am J Med 1980;67:690-4. CrossrefGoogle Scholar4. SIEBERADAMSON SR. Toxicity of neoplastic agents in man; chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential. Adv Cancer Res. 1975;22:57-155. CrossrefMedlineGoogle Scholar1. CARPENTERWINTROBEFULLERHAUTCARTWRIGHT AMEAG. Treatment of idiopathic thrombocytopenic purpura. JAMA. 1959;171:1911-16. CrossrefMedlineGoogle Scholar2. DOANBOURONCLEWISEMAN CBB. Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of 381 cases over a period of 28 years Ann Intern Med. 1960;53:861-76. LinkGoogle Scholar3. HARRINGTONAHNBYRNESSOMYLVAGANAMPALL WYJARL. Treatment of idiopathic thrombocytopenic purpura. Hosp Pract. 1983;18:205-10, 215, 218-20. CrossrefGoogle Scholar4. AHNHARRINGTONSIMONMYLVAGANAMPALLSO YWSRLA. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983;308:1396-9. CrossrefMedlineGoogle Scholar5. Some Antineoplastic and Immunosuppressant Agents. Lyon, France: International Agency for Research on Cancer; 1981:349-63. (IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans; vol. 26.) Google Scholar6. Chemicals, Industrial Processors, and Industries Associated with Cancer in Humans. Lyon, France: International Agency for Research on Cancer; 1982:257-60. (IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans; suppl 4.) Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: MADHAVAN V. PILLAI, M.D.; CORY D. SPENCER, M.D.; TAKUO SONODA, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study 1 July 1984Volume 101, Issue 1Page: 149-150KeywordsAlkaloidsIdiopathic thrombocytopenic purpuraPlatelets ePublished: 1 December 2008 Issue Published: 1 July 1984 PDF downloadLoading ...